In early 2026, China's National Medical Products Administration (NMPA) released a new round of registration review optimizations, accelerating the process for imported drugs with clear clinical value. Products that have completed Phase III trials overseas with robust safety data may see review timelines shortened by 30-40%.
For cross-border pharma companies, this means more predictable planning horizons and lower uncertainty costs. Shuaizhijia Group's regulatory affairs team has completed its policy impact analysis and is adjusting registration strategies and milestone schedules for active partnerships.
The group's regulatory lead noted that the core change is improved predictability of review pathways — a factor that directly influences overseas companies' confidence in committing resources to the China market.
Future updates will continue to focus on compliance, quality and cross-border coordination as key milestones progress.